SCHEMBL6725409

SCHEMBL6725409

c1ccc(-c2nc3cccc(-c4ccccc4)c3nc2-c2ccc(N(c3ccccc3)c3ccccc3)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
L3MBTL1 Q9Y468 4/20 0.44
KDM4E B2RXH2 4/20 0.44
LMNA P02545 4/20 0.44
GAA P10253 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
PSMB5 P28074 1/20 0.41
ALDH1A1 P00352 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM1A O60341 1/20 0.40
MET P08581 1/20 0.39
AKT1 P31749 2/20 0.39
AKT2 P31751 1/20 0.39
PDE10A Q9Y233 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C8 P10632 1/20 0.38
CYP2C9 P11712 1/20 0.38
DHODH Q02127 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12207281 1.00 MEN1 (0.46) MEN1KMT2AL3MBTL1KDM4ELMNA
SCHEMBL12207638 1.00 MEN1 (0.46) MEN1KMT2AL3MBTL1KDM4ELMNA
SCHEMBL6725378 1.00 MEN1 (0.46) MEN1KMT2AL3MBTL1KDM4ELMNA
SCHEMBL12207302 1.00 MEN1 (0.46) MEN1KMT2AL3MBTL1KDM4ELMNA
SCHEMBL12207303 0.98 MEN1 (0.44) MEN1KMT2AL3MBTL1KDM4ELMNA
SCHEMBL6725285 0.98 MEN1 (0.44) MEN1KMT2AL3MBTL1KDM4ELMNA
SCHEMBL12207284 0.98 MEN1 (0.44) MEN1KMT2AL3MBTL1KDM4ELMNA
SCHEMBL12207644 0.98 MEN1 (0.44) MEN1KMT2AL3MBTL1KDM4ELMNA
SCHEMBL6725192 0.98 MEN1 (0.44) MEN1KMT2AL3MBTL1KDM4ELMNA
SCHEMBL12207659 0.94 MEN1 (0.43) MEN1KMT2AL3MBTL1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178216-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-15 US disclosed
US-8178216-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-15 US disclosed
US-20090072718-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-03-19 US disclosed
US-20090072718-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090072718-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative CRY1, GRK1, CRY2 MEN1 974/4885KMT2A 1322/4885L3MBTL1 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.